FindTrial
Sign In

Survey of treatment strategy and analysis of prognostic factors in borderline resectable pancreatic cancer

Survey of treatment strategy and analysis of prognostic factors in borderline resectable pancreatic cancer - Prognostic factors in borderline resectable pancreatic cancer

Status
Unknown
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000021799
Enrollment
700
Registered
2016-04-06
Start date
2016-04-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Sponsors

Tokyo Medical University
Lead Sponsor
Participating institutions of Japanese Society of Pancreatic Surgery
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Borderline resectable pancreatic cancer

Exclusion criteria

Exclusion criteria: Unsuitable case in this study

Design outcomes

Primary

MeasureTime frame
Overall survival—

Secondary

MeasureTime frame
disease-free survival, neoadjuvant theraphy methods, completion rates of neoadjuvant theraphy, RECIST, CA19-9, SUVmax, Pathological effect, R0 resection rate, postoperative complications, postoperative diarrhea rate, readmission rate, completion rates of adjuvant theraphy, the administration period of adjuvant chemotherapy, patterns of recurrence—

Countries

Japan

Contacts

Public ContactYuichi Nagakawa

Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery

naga@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026